Andy Bayliffe

Andy serves as our Chief Development Officer. He joins Quotient with more than 25 years‘ experience spanning pharmaceutical, biotech and venture capital roles. During his 20 years at GlaxoSmithKline Pharmaceuticals, Andy led the discovery and development of numerous drug programs through early and late phases across a broad range of therapy areas, while developing deep expertise in the clinical pharmacology of both small and large molecules. More recently, as a Venture Partner at Apple Tree Partners venture capital firm, Andy co-founded Marengo Therapeutics where, as Chief Scientific Officer, he led the discovery of several novel TCR-targeted antibody platforms for treating autoimmune and oncology diseases. During more than 5 years as CSO at Marengo, Andy led the development of a diverse pipeline of wholly owned and partnered programs in addition to defining the translational pharmacology of lead molecules in Phase ¹⁄₂ clinical trials. Andy has a successful track record collaborating with basic and clinical academics, funding agencies, and regulatory authorities, and continues to publish original research in peer-reviewed journals while contributing to the broader translational science and experimental medicine field through interactions with learned societies and institutions.

He completed his undergraduate and PhD studies in pharmacology, physiology, and molecular biology at Manchester Metropolitan University and Leeds University in the UK.